アビガン、マダニ感染症にも適用　厚労省部会、塩野義コロナワクチンを了承

　厚生労働省の専門部会は２４日、富士フイルム富山化学（東京）が開発した新型インフルエンザ治療薬「アビガン」について、マダニが媒介する感染症「重症熱性血小板減少症候群（ＳＦＴＳ）」の治療薬としても使えるよう適用拡大を了承した。同省によると、承認されればＳＦＴＳの治療薬は世界初。
　塩野義製薬（大阪）が開発し、継続審議となっていた新型コロナワクチン「コブゴーズ」も製造販売の承認を了承した。いずれも厚労省が近く正式承認する見通し。（2024/05/24-19:08）

A Japanese health ministry team Friday approved a proposed use of anti-influenza drug Avigan to treat severe fever with thrombocytopenia syndrome, or SFTS, a tick-borne viral disease.
   If the ministry gives its formal approval, Avigan, developed by Tokyo-based Fujifilm Toyama Chemical Co., will be the world's first therapeutic drug for SFTS, according to the health ministry.
   The team also approved the production and sale of a COVID-19 vaccine developed by Shionogi & Co., based in Osaka, western Japan.
   The ministry is expected to formally approve the expanded use of Avigan and the COVID-19 vaccine shortly.
   According to the National Institute of Infectious Diseases, patients with SFTS contracted through tick bites, develop symptoms such as fever and diarrhea after an incubation period of six to 14 days, with fatality rates standing at 6 to 30 pct.